Navigation Links
Ikaria(R) to Present at 27th Annual JPMorgan Healthcare Conference
Date:1/8/2009

CLINTON, N.J., Jan. 8 /PRNewswire/ -- Ikaria Holdings, Inc. today announced that its President & CEO, Daniel Tasse, will present at the 27th Annual JPMorgan Healthcare Conference on Wednesday, January 14, 2009 at 8:00 a.m., PST. The conference will be held January 12-15 at The Westin St. Francis Hotel in San Francisco.

About Ikaria Holdings, Inc.

Ikaria Holdings, Inc. is a fully integrated biotherapeutics company focused on the development and commercialization of innovative pharmaceuticals and drug-device combinations for hospitalized, critically ill patients. The company's lead product, INOmax(R) (nitric oxide) for inhalation, is the only FDA-approved drug for the treatment of hypoxic respiratory failure in term and near-term newborns(1), and also is marketed in Canada, Europe, Australia and Latin America. INOmax recently was approved for marketing in Japan. Ikaria is engaged in new and ongoing clinical development of INOmax, Covox(R) (carbon monoxide) for inhalation and hydrogen sulfide. Recently, Ikaria acquired the North American rights to terlipressin, which currently is under review by the FDA for the treatment of hepatorenal syndrome Type 1. Ikaria is headquartered in Clinton, NJ, with research facilities in Seattle, WA and Madison, WI, and a manufacturing facility in Port Allen, LA. For more information, please visit www.ikaria.com.

(1) INOmax should not be used in the treatment of neonates known to be dependent on right-to-left shunting of blood. Abrupt discontinuation of INOmax may lead to a worsening condition. Methemoglobinemia is a dose-dependent side effect of inhaled nitric oxide therapy. Nitrogen dioxide (NO2) forms rapidly in gas mixtures containing nitric oxide and oxygen, thus may cause airway inflammation and damage. Methemoglobin, NO2, and Fi2 should be monitored during nitric oxide administration.

For more
'/>"/>

SOURCE Ikaria Holdings, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Ikaria(R) Strengthens Commercial Operations and Human Resources Leadership
2. BioCryst to Present at the J.P. Morgan 27th Annual Healthcare Conference
3. ARCA biopharma to Present at 27th Annual JPMorgan Healthcare Conference
4. Dendreon Announces Webcast Presentation at 27th Annual J.P. Morgan Healthcare Conference
5. Arena Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference
6. VivoMetrics to Present at the 2009 Biotech Showcase
7. OpenClinica to Present at International Conference on Health Informatics, January 14-17, Porto, Portugal
8. Amgen to Present at the 27th Annual JP Morgan Healthcare Conference
9. Par Pharmaceutical to Present at the 27th Annual J.P. Morgan Healthcare Conference
10. Poniard Pharmaceuticals to Present Data from Phase 2 Clinical Trials of Picoplatin in Colorectal and Prostate Cancers
11. Alliance Biosciences Announces Trade Mission to Singapore with Speaker Presentation at International Lab Design Seminar
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , Not for release, publication or distribution (in ... where to do so would constitute a violation of the ... or the "Company") (LSE: SHP, NASDAQ: SHPG ) ... held a meeting with representatives of AbbVie. This ... or approval of AbbVie. A further update will ...
(Date:7/11/2014)... 11, 2014 BCC Research ( http://www.bccresearch.com ... POLYMERASE CHAIN REACTION (PCR) TECHNOLOGY: GLOBAL MARKETS , the ... reached nearly $140 billion in 2013. This is estimated ... five-year compound annual growth rate (CAGR) of 28.6%. , ... interesting and exciting possibilities within the broader PCR field. ...
(Date:7/11/2014)... 2014 /CNW/ - Sunovion Pharmaceuticals Canada Inc. (Sunovion) today ... acetate) for use as a once-daily adjunctive therapy for ... who are not satisfactorily controlled with conventional therapy.  APTIOM ... under 18 years of age. Epilepsy ... according to Epilepsy Canada, it affects 0.6% of the ...
(Date:7/11/2014)... Cayenne Medical, Inc., a privately ... soft tissue reconstruction segment, announced the worldwide launch ... involving the shoulder and extremities. The SureLock System ... deployment method. The unique delivery eliminates manual tensioning ... or anchor displacement (also commonly know as anchor ...
Breaking Biology Technology:Shire plc - Statement re: Media Speculation 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3
... Laboratory (IL) today announced that their Strategic Alliance ... June 22, 2012, after more than twenty successful ... direct sales, service, support and marketing to end-user ... own Hemostasis product line, including the HemosIL® line ...
... Pharmaceuticals today announced that the United States Patent and ... entitled, "Antibodies specific to heterodimers of Bcl-2 family and ... method for extending Eutropics, BH3 profiling technology, which is ... technology assesses the ability of a key part of ...
... 2012  Sangamo BioSciences, Inc. (Nasdaq: SGMO ) announced ... an update on the progress of Sangamo,s ZFP Therapeutic® development ... the following conferences: , The 11th Annual JMP ... PT (6:00 pm ET), on Monday, May 14, 2012. ...
Cached Biology Technology:Instrumentation Laboratory Moves To Direct Distribution Of Hemostasis Product Line In North America 2Instrumentation Laboratory Moves To Direct Distribution Of Hemostasis Product Line In North America 3Eutropics Pharmaceuticals Receives U.S. Patent for Novel Diagnostic Method 2Sangamo BioSciences Announces Presentations At Upcoming Investor Conferences 2
(Date:7/11/2014)... from Salk Institute for Biological Studies, BGI, and ... safety and reliability of the existing targeted gene ... TALEN-HDAdV, which could significantly increased gene-correction efficiency in ... published online in Cell Stell Cell ... gene therapy. , The combination of stem cells ...
(Date:7/11/2014)... July 11, 2014 Researchers have pioneered ... images. The new technology, called Virtual Finger, allows ... structures like neurons and synapses using the flat ... technology makes 3D imaging studies orders of magnitude ... an unprecedented level across many areas of experimental ...
(Date:7/11/2014)... normal circumstances, astrocytes participate in normal physiological ... exhibit therapeutic and repairing effects on brain ... found that nerve cells differentiated from adipose-derived ... viability, which produces influences on subsequent studies ... Hospital, Hebei United University, China demonstrated that ...
Breaking Biology News(10 mins):A new genome editing method brings the possibility of gene therapies closer to reality 2Virtual finger enables scientists to navigate and analyze complex 3D images 2
... of a gene that optimizes their brain's thinking circuitry, ... severe mental illness marked by impaired thinking, scientists at ... Mental Health (NIMH) have discovered. The seeming paradox ... of variation in the human gene for a brain ...
... of epicatechin, a compound found in cocoa, are so striking ... importance to public health, reports Marina Murphy in Chemistry & ... medicine at Harvard Medical School, told C&I that epicatechin is ... , Hollenberg has spent years studying the benefits of cocoa ...
... Researchers from Université Laval’s Faculty of Medicine have ... antiwrinkle products causes a pathological reaction in skin ... present their conclusions about the mode of action ... the British Journal of Dermatology. , DMAE (2-dimethylaminoethanol) ...
Cached Biology News:Common gene version optimizes thinking -- but with a possible downside 2Cocoa 'vitamin' health benefits could outshine penicillin 2Anti-wrinkle compound causes pathological reaction in skin cells 2
The 12-Tube Magnetic Separation Rack is designed to be used for small-scale separations using magnetic particles. ,Capacity: 12 microcentrifuge tubes. ,Magnets: Neodymium rare earth permanent ma...
DONOR BOVINE SERUM AND PLASMA...
12(S)-HETE-d8 is used as an internal standard for the quantification of 12(S)-HETE by stable isotope dilution mass spectrometry....
...
Biology Products: